Sufficiency for inducible Caspase-9 safety switch in human pluripotent stem cells and disease cells
Toshinobu Nishimura(Stanford University), Hiromitsu Nakauchi(University of Tsukuba), Manami Ohtaka(National Institute of Advanced Industrial Science and Technology), Michael L. Cleary(Stanford University), Daiki Karigane(Keio University), Renata M. Martin(Stanford University), Scott R. Burrows(QIMR Berghofer Medical Research Institute), Fabian P. Suchy(California Institute for Regenerative Medicine), Masayuki Iwasaki(Tokyo Women's Medical University), Ravindra Majeti(Stanford University), Yusuke Takahashi(Stanford University), Shinichiro Monobe(Stanford University), Akira Shibuya(ShinEtsu Chemical (Japan)), Haojun Xu(University of Tsukuba), Brandon Saavedra(Stanford University), Mahito Nakanishi(National Institute of Advanced Industrial Science and Technology)
Cited by 13
Related Papers
First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers
|Journal of Clinical Oncology|2019|590
Disrupting the CD47-SIRPα anti-phagocytic axis by a humanized anti-CD47 antibody is an efficacious treatment for malignant pediatric brain tumors
|Science Translational Medicine|2017|427
Development of Defective and Persistent Sendai Virus Vector
|Journal of Biological Chemistry|2010|373
NCRs and DNAM-1 mediate NK cell recognition and lysis of human and mouse melanoma cell lines in vitro and in vivo
|Journal of Clinical Investigation|2009|331
Antibody therapy targeting the CD47 protein is effective in a model of aggressive metastatic leiomyosarcoma
|Proceedings of the National Academy of Sciences|2012|256